These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37092904)

  • 41. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
    Earland N; Chen K; Semenkovich NP; Chauhan PS; Zevallos JP; Chaudhuri AA
    Semin Radiat Oncol; 2023 Jul; 33(3):262-278. PubMed ID: 37331781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives.
    Grizzi G; Salati M; Bonomi M; Ratti M; Holladay L; De Grandis MC; Spada D; Baiocchi GL; Ghidini M
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
    Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
    Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.
    Watanabe K; Nakamura T; Kimura Y; Motoya M; Kojima S; Kuraya T; Murakami T; Kaneko T; Shinohara Y; Kitayama Y; Fukuda K; Hatanaka KC; Mitsuhashi T; Pittella-Silva F; Yamaguchi T; Hirano S; Nakamura Y; Low SK
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers.
    Allan Z; Liu DS; Lee MM; Tie J; Clemons NJ
    Clin Chem; 2024 Jan; 70(1):49-59. PubMed ID: 38175583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
    Chae YK; Oh MS
    J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
    Sun Y; Zhu C; Xu F; Cui S; Guan X
    Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
    Malla M; Parikh AR
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
    Marmorino F; Prisciandaro M; Giordano M; Ortolan E; Crucitta S; Manca P; Antoniotti C; Valenti MM; Danesi R; Conca V; Mazzoli G; Boccaccino A; Carullo M; Martinetti A; Sottotetti E; Masi G; Sposito C; Zaffaroni N; Milione M; Fontanini G; Del Re M; Pietrantonio F; Cremolini C
    JCO Precis Oncol; 2022 Nov; 6():e2200244. PubMed ID: 36356286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
    Huffman BM; Aushev VN; Budde GL; Chao J; Dayyani F; Hanna D; Botta GP; Catenacci DVT; Maron SB; Krinshpun S; Sharma S; George GV; Malhotra M; Jurdi A; Moshkevich S; Aleshin A; Kasi PM; Klempner SJ
    JCO Precis Oncol; 2022 Dec; 6():e2200420. PubMed ID: 36480779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
    Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
    Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
    Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory implications of ctDNA in immuno-oncology for solid tumors.
    Vellanki PJ; Ghosh S; Pathak A; Fusco MJ; Bloomquist EW; Tang S; Singh H; Philip R; Pazdur R; Beaver JA
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
    van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
    Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.